Without adequate power, that 24% reduction is not a reliable number. Based on statistics, with such a low power, leronlimab could have reduced mortality by 23% partially due to chance. Sorry but that's just how the FDA will view the numbers. Janet Woodcock has continually reinforced that they are interested in adequately powered trials.